These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 33901406)

  • 21. Identification of Potential Leukocyte Biomarkers Related to Drug Recovery of CFTR: Clinical Applications in Cystic Fibrosis.
    Pedrazzi M; Vercellone S; Barberis E; Capraro M; De Tullio R; Cresta F; Casciaro R; Castellani C; Patrone M; Marengo E; Lecca P; Melotti P; Sorio C; Manfredi M; Averna M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States.
    Thorat T; McGarry LJ; Jariwala-Parikh K; Limone B; Bonafede M; Chandarana K; Konstan MW
    Pulm Ther; 2021 Jun; 7(1):281-293. PubMed ID: 33913076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sweat sticker for cystic fibrosis.
    Basson M
    Nat Med; 2021 Apr; ():. PubMed ID: 33903773
    [No Abstract]   [Full Text] [Related]  

  • 24. Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study.
    Migliorisi G; Collura M; Ficili F; Pensabene T; Bongiorno D; Collura A; Di Bernardo F; Stefani S
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increasing life expectancy in cystic fibrosis: Advances and challenges.
    McBennett KA; Davis PB; Konstan MW
    Pediatr Pulmonol; 2022 Feb; 57 Suppl 1(Suppl 1):S5-S12. PubMed ID: 34672432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
    Bitonti M; Fritts L; So TY
    J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Future of Highly Effective Modulator Therapy in Cystic Fibrosis.
    Daines CL; Morgan WJ
    Am J Respir Crit Care Med; 2021 Jun; 203(12):1453-1455. PubMed ID: 33901406
    [No Abstract]   [Full Text] [Related]  

  • 29. Cystic fibrosis transmembrane conductance regulator biomarkers in 'real life': can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?
    van Koningsbruggen-Rietschel S; Naehrlich L
    Ther Adv Respir Dis; 2015 Aug; 9(4):198-200. PubMed ID: 26175480
    [No Abstract]   [Full Text] [Related]  

  • 30. A New Era for Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator Modulator Trials in Infants.
    Wainwright CE
    Am J Respir Crit Care Med; 2022 Nov; 206(10):1193-1195. PubMed ID: 35856818
    [No Abstract]   [Full Text] [Related]  

  • 31. Therapy for cystic fibrosis--the end of the beginning?
    Davis PB
    N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
    [No Abstract]   [Full Text] [Related]  

  • 32. COUNTERPOINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No.
    Thursfield RM; Shafi N; Davies JC
    Chest; 2022 Jan; 161(1):21-24. PubMed ID: 35000702
    [No Abstract]   [Full Text] [Related]  

  • 33. In response to "who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies".
    McGarry ME; McColley SA; Taylor-Cousar J
    Respir Med; 2022 Oct; 202():106953. PubMed ID: 36049345
    [No Abstract]   [Full Text] [Related]  

  • 34. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One
    Zemanick ET; Taylor-Cousar JL; Davies J; Gibson RL; Mall MA; McKone EF; McNally P; Ramsey BW; Rayment JH; Rowe SM; Tullis E; Ahluwalia N; Chu C; Ho T; Moskowitz SM; Noel S; Tian S; Waltz D; Weinstock TG; Xuan F; Wainwright CE; McColley SA
    Am J Respir Crit Care Med; 2021 Jun; 203(12):1522-1532. PubMed ID: 33734030
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.
    McGarry ME; McColley SA
    Pediatr Pulmonol; 2021 Jun; 56(6):1496-1503. PubMed ID: 33470563
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.